Penn Medicine offers one of the only dedicated neuroendocrine tumor (NET) programs in the country with the combined expertise to treat both gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pheochromocytomas and paragangliomas (PHEOs). Our program is the first and only one of its kind in the region.
Following the diagnosis and staging of neuroendocrine tumors, our cancer specialists at Penn Medicine's Abramson Cancer Center develop a personalized treatment plan that's right for you.
Azedra, the First-Ever FDA-Approved Non-Surgical Treatment for Rare Neuroendocrine Cancers
Recently, the US Food and Drug Administration (FDA) approved the first-ever non-surgical treatment for the rare neuroendocrine cancers, pheochromocytoma and paraganglioma. The approval was based largely on the results of the Penn-led trial involving 68 patients who benefitted from receiving at least one therapeutic dose of Azedra.
To learn more about Azedra:
If you or a loved one has neuroendocrine cancer, you can find out if Azedra is a possible treatment option by calling 800-789-7366.
Other Treatment Options for Neuroendocrine Cancers
In addition to Azedra, we offer the following treatment options for neuroendocrine tumors:
- Local and local-regional excision
- Debulking surgery, including liver resection
- Laparoscopic cortical sparing surgery
- Liver transplantation
- Radiofrequency ablation
- Chemotherapy and biologic therapies, such as hormone therapy and octreotide
- Proton pump inhibitors (PPIs)
- Liver-directed therapies
- Ethanol injection
- Chemoembolization of the hepatic artery
- Targeted therapy
- External-beam radiation therapy